Murray, Frank & Sailer LLP has filed a class action complaint, in the Southern District of Texas Houston Division, against Repros Therapeutics, Inc. (Nasdaq: RPRX) and certain of its officers and directors, on behalf of shareholders who purchased Repros common stock between July 1, 2009 and August 3, 2009.
The complaint alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by issuing materially false and misleading press releases regarding the success of clinical trials for its drug Proellex. On August 3, 2009, Repros revealed that it was suspending Proellex clinical trials based in a clinically significant increase in liver enzymes among participants. On that day, Repros stock closed at $1.31, a 48% drop from a close of $2.53 the trading day before. This was a 73% drop from the close of $4.96 on July 1, 2009.
Plaintiff seeks to recover damages on behalf of class members and is represented by Murray, Frank & Sailer LLP, a law firm with extensive experience in prosecuting shareholder lawsuits.
If you are a member of the class described above, you may move the Court, not later than October 6, 2009, to serve as Lead Plaintiff for the class. A Lead Plaintiff is a representative chosen by the Court who acts on behalf of other class members in directing the litigation. You do not need to be a Lead Plaintiff to be included in the class. If you purchased Repros common stock and wish to discuss this litigation, or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact us.
Contacts:
Murray, Frank & Sailer LLP
Eva Hromadkova
212-682-1818
800-497-8076
newcase@murrayfrank.com
www.murrayfrank.com
